All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
with Paolo Gisondi, Andrew Alexis, and Mona Shahriari
Thursday, February 6, 2025
16:00-17:00 GMT
This independent educational activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Bimekizumab for scalp, nail, and palmoplantar psoriasis: 2-year pooled analysis
|
Plaque psoriasis impacts areas such as scalp, nails, palms, and soles leading to inferior patient QoL. Merola et al. published the results of a 2-year pooled analysis from five phase III/IIIb trials (NCT03370133, NCT03410992, NCT03412747, NCT03598790, and NCT03536884) evaluating the efficacy of bimekizumab in 1,107 patients with moderate-to-severe plaque psoriasis in Dermatology and Therapy.1
|
| Key learnings |
| Rapid scalp clearance was achieved by 83.7% at Week 16 among patients with scalp IGA ≥3 at baseline (n = 821). Responses were maintained in 86.4% of patients at Y1 and 85.9% of patients at Y2. |
| Among patients with mNAPSI >10 at baseline, rates of complete nail clearance increased to 63.4% and 69.1% at the end of Y1 and remained stable at 68.5% and 69.9% at Y2 in the bimekizumab total and Q4W/Q8W groups, respectively. |
| At Week 16, 87.4% of patients in the bimekizumab total group achieved palmoplantar clearance. High rates of complete response were sustained at Y1 and Y2 in 88.3% and 89.8% and 94.2% and 88.5% of patients in bimekizumab total and Q4W/Q8W groups, respectively. |
| These results show that bimekizumab was effective and provided sustained responses over 2 years in high-impact areas in patients with moderate-to-severe plaque psoriasis. |
Abbreviations: IGA, Investigator’s Global Assessment; mNAPSI, modified Nail Psoriasis Severity Index; Q4W, every 4 weeks; Q8W, every 8 weeks; QoL, quality of life; Y1, Year; Y2, Year 2.
Merola JF, Gottlieb AB, Pinter A, et al. Bimekizumab efficacy in high-impact areas: Pooled 2-year analysis in scalp, nail, and palmoplantar psoriasis from phase 3/3b randomized controlled trials. Dermatol Ther (Heidelb). 2024;14(12):3291-3306.
Your opinion matters
13 votes - 18 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox